Kwality Pharmaceuticals working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY24Mar 2024FY23Mar 2023FY22Mar 2022
196.22×231.59×97.09×
112.45×104.70×56.58×
94.73×115.58×62.80×
213.94×220.71×90.87×
3.36×3.08×—
0.81×0.72×1.33×
——0.53×
—0.70×0.37×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KPL₹3,680.60

Kwality Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Inventory Days (DIO)97.09231.59196.22
Receivable Days (DSO)56.58104.70112.45
Payable Days (DPO)62.80115.5894.73
Cash Conversion Cycle (days)90.87220.71213.94
Working Capital Turnover—3.083.36
Asset Turnover1.330.720.81
Cash Conversion (CFO/Net Income)0.53——
CFO/EBITDA0.370.70—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.